Deng Y, et al. - Authors assessed the association of oral bisphosphonates (BPs) with the incidence of 13 specific cancer types (including lung, esophageal, gastric, and colorectal cancer) in patients with osteoporosis. Two investigators independently and systematically retrieved relevant studies published in databases (eg, PubMed, Embase database, and Cochrane library) from inception to August 25, 2018, regardless of language. A total of 13 cohort studies involving 1,510,763 participants were included in the meta-analysis. Overall, they investigators found that the risk of incidence of all-cause cancer is not increased by oral BPs; rather oral BPs can reduce the incidence of breast, endometrial, and upper gastrointestinal cancers in postmenopausal women with osteoporosis. Their analysis stratified by sex, however, indicated that oral BPs may increase the liver cancer incidence in mixed genders, but there was no significant link noted in women.